Human Papillomavirus Quadrivalent (types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®): A Viewpoint by Daron G. Ferris

Author： Ferris Daron G.  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.66, Iss.9, 2006-01, pp. : 1272-1273

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Human Papillomavirus Quadrivalent (types 6, 11, 16, 18) Recombinant Vaccine (Gardasil ® )

By Siddiqui M. Asif A.   Perry Caroline M.  

Drugs, Vol. 66, Iss. 9, 2006-01 ,pp. : 1263-1271

Adis International

Access to resources Recommend Favorite

Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®): A Review of its Use in the Prevention of Premalignant Genital Lesions, Genital Cancer and Genital Warts in Women

By McCormack Paul L.  

Drugs, Vol. 70, Iss. 18, 2010-12 ,pp. : 2449-2474

Adis International

Access to resources Recommend Favorite

Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine: For the Prevention of Genital Warts in Males

By Garnock-Jones Karly P.  

Drugs, Vol. 71, Iss. 5, 2011-03 ,pp. : 591-602

Adis International

Access to resources Recommend Favorite

Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine for the Prevention of Genital Warts in Males†: Profile Report

By Garnock-Jones Karly P.  

Drugs in R&D, Vol. 12, Iss. 4, 2012-12 ,pp. : 235-238

Adis International

Access to resources Recommend Favorite

Sanofi Pasteur MSD's recombinant quadrivalent human papillomavirus (HPV) vaccine [Gardasil] has been launched in 15 EU countries

By  

Inpharma, Vol. 1, Iss. 1575, 2007-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite